Skip to main content
Clinical Trials/ISRCTN16838474
ISRCTN16838474
Completed
未知

Post-marketing observational study to follow-up patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis who are treated with ExemptiaTM (Adalimumab).

Cadila Healthcare Ltd.0 sites149 target enrollmentFebruary 6, 2019

Overview

Phase
未知
Intervention
Not specified
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis
Sponsor
Cadila Healthcare Ltd.
Enrollment
149
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

2019 results in patients with rheumatoid arthritis in: https://www.ncbi.nlm.nih.gov/pubmed/31254222 (added 09/07/2019) 2019 results in patients with ankylosing spondylitis in: https://www.ncbi.nlm.nih.gov/pubmed/31777828 (added 02/12/2019)

Registry
who.int
Start Date
February 6, 2019
End Date
November 30, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. \=2 years up to 75 years old
  • 2\. Diagnosis as per current guidelines published by ACR/EULAR/CASPAR/ILAR guidelines of:
  • 2\.1\. Rheumatoid Arthritis
  • 2\.2\. Ankylosing Spondylitis
  • 2\.3\. Psoriatic arthritis
  • 2\.4\. Juvenile Idiopathic Arthritis (JIA)
  • 3\. Treatment with ExemptiaTM (Adalimumab)
  • 4\. Subjects and/or their parent/ legal guardian were willing to be contacted in the future by study staff.

Exclusion Criteria

  • 1\. Subjects receiving Adalimumab other than ExemptiaTM (Adalimumab)
  • 2\. Any contraindication for ExemptiaTM (Adalimumab) or concomitant drug like CNS and myeloid disorders according to Prescribing Information

Outcomes

Primary Outcomes

Not specified

Similar Trials